Efficacy and Safety of Slow Mohs Micrographic Surgery for Treating Nail Apparatus Melanoma in Situ
abstract
This abstract is available on the publisher's site.
Access this abstract nowBACKGROUND
Nail apparatus melanoma is a malignant tumor with a high incidence in Chinese melanoma patients. Slow Mohs micrographic surgery is an emerging technique for treating nail apparatus melanoma in situ (NAMIS).
OBJECTIVE
This study evaluated the efficacy and safety of slow Mohs micrographic surgery for treating NAMIS.
METHODS
Patients were enrolled in this retrospective study and treated in a single center from October 1, 2016, to June 30, 2022. Each patient underwent standard slow Mohs micrographic surgery, and follow-up was regularly conducted at clinics.
RESULTS
Ten patients were enrolled in the study. Two patients underwent one Mohs stage, seven underwent two Mohs stages, and one underwent seven Mohs stages. The resection margin ranged from 5 to 25 mm. No severe complications were reported in the treatment, and recurrence of NAMIS was not observed during the follow-up period.
CONCLUSION
Slow Mohs micrographic surgery is a valuable surgical method to treat NAMIS that preserves digit function and can be well tolerated by patients.
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Slow Mohs micrographic surgery for nail apparatus melanoma in situ
Int. J. Dermatol 2023 Jun 23;[EPub Ahead of Print], S Zhang, Y Wang, K Fang, Q Jia, H Zhang, T QuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The two articles by Le and Zhang provide real-world evidence that Mohs surgery is an effective treatment for melanoma in situ (MIS) of the nail unit. Is this evidence-based practice changing? The preponderance of evidence to date, including these articles, confirms that Mohs is at least non-inferior. There are no randomized controlled trials, nor will there likely be one. But, as pointed out in a recent JAMA article, real-world evidence has a meaningful role in health care decision-making, and this evidence supports the value of Mohs surgery in nail unit MIS.1,2 Although the number of patients is small, comparison of raw recurrence rates may be misleading; the pooling of data helps to strengthen the evidence.
These reports have weaknesses repeated in many case studies and reviews. First, they do not define local recurrence. All studies should define local persistence and separate persistent disease recurrence from satellite metastatic disease. This might be a moot point because these reports were for MIS, and any local recurrence was likely due to persistent disease; nonetheless, the distinction is important. Second, follow-up time is extremely important. Most local recurrences from persistent disease occur later than metastatic disease (5 years vs 2 years). All studies should specify how long patients were followed, and Kaplan–Meier statistics should help extrapolate the data to provide a projected 5-year recurrence rate.
My opinion based on my treatment of dozens of nail unit MIS is that Mohs is extremely valuable when performed properly. Mohs surgery with frozen sections and Mart 1 immunostaining is the most accurate way to assess the margin. The use of blue Mart 1 improves detection of melanocytes.3 Fellowship training is valuable due to the increased difficulty of removing layers from the nail bed, periosteum, nail horns, and even bone when necessary. In the end it all comes down to – should 100% of the margin be examined by Mohs, or is it good enough to sample less than 1% of the margin with traditional pathology exam? The controversies about the value of Mohs surgery for melanoma are melting away.
References